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Abstract: For the continuous registration of thrombin formation in plasma (1) selective thrombin 
substrates are required, that show moderate binding affinities (high K,) and low 
turnover numbers (low bat). Previously we have used SQ68 (CHsO-CO-CHz-CO- 
Aib-Arg-pNA) for this purpose. In order to find more substrates suitable for this 
application, we synthesized a series of 25 peptide p-nitroanilides. As lead structures 
SQ68 and S2238 (H-D-Phe-Pip-Arg-pNA) were used. By introduction of specific 
structure modifications we tried to alter the kinetic data in the required direction. The 
modifications were designed on basis of existing knowledge on the structure of the 
thrombin active-site and its surroundings, We indeed obtained a number of substrates 
with the kinetic constants in the desired range. 
For the continuous registration of thrombin generation and the determination of the endogenous 
thrombin potential (ETP: area under the thrombin generation curve) it is necessary to dispose of 
specific thrombin substrates that are converted at a slow rate so as not to be exhausted when 
added to clotting plasma (1). The suitable substrate that is now available (Serbio SQ68), was 
found by accident. Published modeling and X-ray analyses of the thrombin molecule offer insight 
into the three-dimensional form of its active-site and suggest modifications of existing thrombin 
substrates that may serve to tune the kinetic parameters in the required direction. In this article 
we report the results of a synthetic search for specific, slow reacting thrombin substrates. 
Current research focusses on H-D-Phe-Pip-Arg-pNA (S2238) as a lead structure in the 
development of highly specific thrombin inhibitors, Derivatives of this structure containing 
aldehyde- (2) chloromethylketone- (3) aminoboronic acid- (4), ketomethylene- (5) and 
aminophosphonic acid- (6) functions were described as potent and specific transition-state 
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analogue inhibitors of thrombin. All these inhibitors contain an arginine in the PI position 
corresponding to the primary specificity of thrombin. 
Recent publications showed that inhibitors derived from H-D-Phe-Pip-Arg that, at position PI, 
contain an amino acid with a neutral side chain show enhanced selectivity towards thrombin. 
A~O, substances in which the positively charged side chain of arginine is replaced by a neutral 
side chain, containing aldehyde- (7) aminoboronic acid- (8) and aminophosphonic acid- (9) 
functions bind tightly to thrombin. This result is somewhat surprising, because it was believed 
that electrostatic interaction between the positively charged guanidino group of inhibitors and 
substrates, and the negatively charged Asp189 residue in the primary specificity pocket of 
thrombin is essential for complex formation. The crystal structure of human a-thrombin 
complexed with H-D-Phe-Pro-Arg-CH$l, however, showed that the active-site consists of two 
important binding regions: the hydrophobic binding pocket, SZ subsite, which interacts 
preferentially with proline residues, and the aryl-binding pocket (S3) in which aromatic stacking 
interactions (D-phenylalanine) are of major importance for strong binding aflinity (10-I 1). The 
fact that inhibitors containing the H-D-Phe-Pro sequence with a modified PI residue still bind to 
thrombin can be explained in terms of these binding interactions, Also, the inhibitors containing 
amino acids with neutral side chains at the PI position show enhanced selectivity towards 
thrombin compared to other serine proteases with an arginine as primary determinant of 
specificity. Comparison of the SI binding pockets of thrombin, trypsin and plasmin showed that 
the Sl binding pocket of thrombin is the most hydrophobic one. This explains why a neutral side 
chain at Pl would be better accommodated by thrombin than by trypsin or plasmin. The 
improvement of selectivity is paid by a decrease of potency as a result of a loss in electrostatic 
binding interactions with Asp189. 
These findings motivated us to try and synthesize pNA-substrates with maintenance of the H-D- 
Phe-Pip(Pro) sequence and in which the PI amino acid residue is varied, see table I. 
Another starting point was CHsO-CO-CH2-CO-Aib-Arg-pNA (SQ68) (12). At position P2 and 
P3, this substrate has not the optimal structural elements for interaction with thrombin. We 
started an investigation into a structure-activity relationship to obtain substrates selective for 
thrombin, in which a dipeptide is the smallest determinant of selectivity, the case being modified 
at its N-terminus to mimic a P3 residue. From modeling studies (13-14) and homology model- 
building (15) it has been concluded that the p-naphtalenesulfonyl function interacts with thrombin 
in a highly specific manner, whereas interaction with other serine proteases is minimal. The p- 
toluenesulfonyl group showed the same binding interactions as the p-naphthalenesulfonyl moiety, 
albeit to a somewhat lesser extent (16). These findings were confirmed by X-ray studies of 
thrombin-complexes formed with active-site directed inhibitors containing these structural 
elements (17- 18). We used both functions to arrive at more selective thrombin substrates. 
EXPERIMENTAL PROCEDURES 
General 
1H Nuclear magnetic resonance (NMR) spectra were recorded on Bruker AM 100 and Bruker 
AM 400 spectrometers (Palo Alto, USA). As an internal standard the residual solvent peak was 
used. Chemical shifts are given in part per million (ppm). Optical rotations were measured on a 
Perkin Elmer 241 polarimeter in a 10 cm cuvette at room temperature. Melting points were 
determined with a Buchi melting point apparatus (Tottoli). Thin layer chromatography (TLC) 
was performed on Merck Silicagel 6OF25, plates (Darmstadt, Germany), and column 
chromatography on Merck Kieselgel 60, 70-230 Mesh ASTM. Spots were detected by UV- 
fluorescence quenching, ninhydrine (free amino hmctions), chlorine/TDM (4,4’-tetramethyl- 
diaminodiphenylmethane, NH groups), Barton’s- (hydrazides) and Sakaguchi’s (arginine residues 
reagent. Methanol was refluxed on magnesium turnings for two hours, distilled and stored on 3 d 
molsieves. Pyridine was distilled over KOH pellets and stored on 4A molsieves. tert.- 
Butyloxycarbonyl (Boc)-amino acids were synthesized by the method of Schnabel (19). Amino 
acid p-nitroanilides were prepared as described by us (20). 
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TABLE I 
Substrates of the Type H-D-Phe-Y-X-pNA and Y-X-Arg-pNA with S2238 respectively 
SQ68 as Lead Structures. 
H-D-Phe-Y-X-pNA 
Y X 
Pip LYS 
Pip OlTl 
Pip Glu 
Pip Nle 
Pro LYS 
Pro Nle 
Y-X-Arg-pNA 
Y X 
Mz GUY 
GUY 
Dh4MZ GUY 
DEMZ GUY 
Nas GUY 
Tos GUY 
Mz Ala 
Ala 
DMMZ Ala 
Mz D-Ala 
Mz Val 
Mz D-W 
Code 
la 
lb 
lc 
Id 
2a 
2b 
Derived from Code 
H-D-Phe-Pip-Arg-pNA 1 
HD-Phe-Pro-Arg-pNA 2 
Derived from 
H-Gly-Arg-pNA 
H-Ala-Arg-pNA 
H-D-Ala-Arg-pNA 
H-Val-Arg-pNA 
H-D-Val-Arg-pNA 
Code 
3 
Code 
3a 
3b 
3c 
3d 
3e 
3f 
4a 
4b 
4c 
Sa 
6a 
la 
Unprotected amino functions are suitably protonated (HCl) to give neutral solutions in plain water. 
Malonic acid and dimethylmalonic acid were converted to their corresponding dimethyl esters by 
heating the dicarboxylic acid with an excess of methanol in the presence of concentrated sulf%c 
acid. Dimethyl methylmalonate was prepared by generating the mono-sodio derivative of 
dimethylmalonate which reacts with methyl iodide via a SN2 mechanism. The corresponding half 
esters were prepared by controlled partial hydrolysis of the diester with one equivalent of 
potassium hydroxide. The monomethyl ester of diethylmalonic acid was obtained in a direct way 
by refluxing the acid in an excess of methanol with sulfkic acid as catalyst. Dimethylmalonic acid 
and L-pipecolic acid were from Janssen Chimica (Geel, Belgium)? diethylmalonic acid was from 
Aldrich (Bornem, Belgium). TDM, naphthalene-2-sulfonyl chloride, toluene-s-sulfonyl chloride 
and D-alanine were obtained from Fluka (Buchs, Switzerland). Boc-Nle-OH, and Fmoc- 
Orn(Boc)-OH were from Bachem (Bubendorf Switzerland). D-Phenylalanine was a generous gift 
of Dr. J. Kamphuis (DSM Research, Geleen, The Netherlands). 
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Syntheses 
Boc-D-Phe-Pip-Nf13 : 
To a solution of Boc-D-Phe-OH (19.88 g, 75 mmol) in EtOAc (350 mL) was added HCl.H-Pip- 
OMe (21) (13.46 g, 75 mmol), HOBt (12.62 g, 82.5 mmol) and NMM (8.75 mL, 78.7 mmol). 
The obtained suspension was cooled on ice and DCC (16.22 g, 78.7 mmol) was added. After 
stirring for two hrs at O°C and 16 hrs at room temperature, DCU was filtered off, The EtGAc 
solution was washed with 2N KHSO,, H,O, saturated NaHC03 and brine (four times 50 mL 
each). The EtOAc layer was dried (Na$SO,), filtered and evaporated in vacua, yielding a clear 
oil, yield: 21.52 g (74%). This product was checked by TLC on purity and directly used for 
further synthesis (Rf(CH.$&/MeOH 9:l v/v): 0.87). The protected dipeptide methyl ester was 
dissolved in MeOH (150 mL) and N,H,.H,O (13.5 mL, 278 mmol) was added. This reaction 
mixture was left for three days at room temperature. The formed precipitate was filtered and 
dried; yield: 15.01 g (70%) Rt(CH,C12/MeOH 9: 1 v/v): 0.54, [a],, = -77.10 c = 0.98 DMF, mp: 
202-204OC, ‘H NMR (CDsOD): ?I = 1.15-l .38 (m, 6H, CHZ-Pip (3 x 2H)); 1.44 (s, 9H, Boc); 
3.08i3.18 (dm, 2H, p-CH;?-Phe); 3.28 (m, 2H, N-CH2-Pip); 4.58 (m, lH, a-CH-Pip); 4.74 (m, 
lH, c*-CH-Phe); 7.20-7.33 (m, 5H, arom Phe). 
Boc-D-Phe-Pip-X-pNA 
a) X = Orn(Boc): 
Boc-D-Phe-Pip-N,H, (0.39 g, 1.0 mmol) was dissolved in DMF (10 mL) and cooled to -2OoC. 
To this solution was added 2.3 M HCI/EtOAc (1.20 mL, 2.75 mmol) followed by Wt.-BuONO 
(0.114 mL, 1.20 mmol). This reaction mixture was stirred for 15 min at -2OoC. (After this period 
the azide-formation was complete.) The acid solution was neutralized by adding DIPEA (0.48 
mL, 2.77 mmol). H-Orn(Boc)-pNA (0.328 g, 1.0 mmol) was added. This reaction mixture was 
kept on neutrality by adding DIPEA at regular time intervals. The obtained reaction medium was 
allowed to react during 16 hrs at OOC. After this period the DMF phase was removed in vacua 
and the oily residue was dissolved in EtOAc (10 mL). The EtOAc solution was washed with 
H,O, 2N KHS04, H20 saturated NaHCO, and brine (three times 5 mL each). The EtOAc 
solution was dried (Na,SO,), filtered and evaporated in vacua. Boc-D-Phe-Pip-Orn(Boc)-pNA 
was purified by column chromatography on silica gel with CH2C12/MeOH 982 v/v as eluens. 
Yield: 0.525 g (74%) Rt(CH2C12/MeOH 98:2 v/v): 0.22, [aID = -64.8O c = 0.13 MeOH, ‘H 
NMR (CD,OD): F = 1.26-1.48 (bm, 6H, CH2-Pip (3 x 2H)); 1.34 (s, 9H, Boc); 1;41 (s, 9H, 
Boc); 1.56/1.65 (dm, 2H, r-CH2-Orn); 1.78/1.99 (dm, 2H, p-CH2-Orn); 2.97 (m, 2H, p-CH2- 
Phe); 3.07 (m, 4H, &CH2-Orn/N-CH2-Pip); 4.48 (m, 2H, IX-CH-Orr&CH-Pip); 4.79 (m, lH, CL- 
CH-Phe); 7.25-7.32 (m, 5H, arom Phe); 7.86/7.88-g. 18/8.20 (dd, 4H, arom pNA). 
b) X = Glu(OtBu) 
Obtained as described for a). 
Yield: 0.422 g (62%) Rt(CH2C12/MeOH 98:2 v/v): 0.44! [aID = -78.5O c = 0.33 MeOH, ‘H 
NMR (CD,OD): S = 1.26-1.54 (bm, 8H, ~-CH~-G~U/CH~-PI~ (3 x 2H)); 1.33 (s, 9H, OfBu); 1.43 
(s, 9H, Boc); 2.38 (m, 2H, r-CH2-Glu); 2.96 (m, 2H, P-CH2-Phe); 3.08 (m, 2H, N-CH2-Pip); 
4.53 (dd, lH, CZ-CH-Glu); 4.59 (m, lH, cL-CH-Pip); 4.82 (m, lH, u-CH-Phe); 7.26-7.33 (m, 5H, 
arom Phe); 7.89/7.91-8.20/8.22 (dd, 4H, arom pNA). 
nHCl.H-D-Phe-Pip-X-pNA 
The protected tripeptide was dissolved in AcOH (lmmol in 5 mL). To the solution 2.3 M 
HWEtOAc (10 mL for 1 mmol) was added and the reaction mixture was stirred until 
deprotection was complete. The acid was quenched with tert. -BuOH (10 mL) and evaporated in 
vacua. The residue was coevaporated with terr.-BuOH (twice) and with MeOH (once). The 
residue was dissolved in H20 and lyophilized. Crude tripeptides were purified by counter current 
distribution with BuOH/AcOH/H,O 4: 1: 5 v/v/v as solvent system. 
a) n = 2, X = Orn (lb): 
L 
Yield: 0.315 (96%) Rt(BuOWAcOH/H20 4 
0.18 MeOH, H NMR (CD,OD): S = 1.29-1.49 (m, 6H, CH2-Pip (3 x 2H)); 1.62:1. F 
!:l:l v/v/v): 0.42 (K = 0.71) [c+ = -96.7O c = 
77 (dm, 2H, 
r-CH2-Om); 2.00-2.15 (dm, 2H, p-CH,-Om); 2.98 (m, 6H, p-CH2-Phe/N-CH,-Pip/&CH2-Om); 
4.34 (m, lH, cL-CH-Pip); 4.46 (m, lH, a-CH-Om); 4.57 (m, lH, cL-CH-Phe); 7.23-7.35 (m, 5H, 
arom Phe); 7.85/7.87-8.20/8.22 (dd, 4H, arom pNA). 
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b) n r I, X = Glu (1~): 
Yield: 0.158 
f 
(64%) Rt(BuOWAcOHH~O 4:l:l v/v/v): 0.67 (K = 5.15) [a]D = -107.4O c = 
0.22 MeOH, H NMR (CD,OD): 6 = 1.1 l-l.35 (m, 6H, CH,-Pip (3 x 2H); 2.03 (m, 2H, p-CH,- 
Glu); 2.26/2.42 (dm, 2H, r-CHz-Glu); 2.82/3.55 (dm, 2H, N-CH,-Pip); 3.1 l/3.24 (dm, 2H, p- 
CH2-Phe); 4.17 (m, lH, a-CH-Glu); 4.52 (m, IH, a-CH-Pip); 4.82 (m, lH, a-CH-Phe); 7.26- 
7.41 (m, 5H, arom Phe); 7.8417.86-8.1918.22 (dd, 4H, arom pNA). 
Boc-X-A t-g-pNA. HCI 
a) X = Gly: 
Boc-Gly-OH (1.75 g, 10 mmol), 2HCl.H-Arg-pNA (3.67 g, 10 mmol), HOBt (1.60 g, 10.1 
mmol) and NMM (1.10 mL, 10.0 mmol) were dissolved in DMF (75 mL). This reaction mixture 
was cooled on ice and DCC (2.16 g, 10.5 mmol, 1.05 eq.) was added. After stirring for 1 hr at 
O°C and 16 hrs at room temperature, DCU was filtered off and DMF was removed under reduced 
pressure. The residue was purified by counter current distribution with BuOWAcOH/H~O 4: 1:5 
v/v/v (K = 1.84) as the solvent system. Pure product was lyophilized from AcOH. Yield: 4.29 g 
(88%), R~BuOWAcOH&O 4: 1 :l V/V/V): 0.64, [a]D = -36.8O c = 0.63 MeOH. 
b) X = Val: 
Obtained as described for a). 
Yield: 2.36 g (89%) Rr-(BuOWAcOH/HZO 4: 1: 1 v/v/v): 0.69 (K = 2.1 l), [a]D = -44.40 c = 0.59 
MeOH, ‘H NMR (CDsOD): 6 = 0.94-0.98 (dd, 6H, r-CH&-CHs-Val); 1.44 (s, 9H, Boc); 1.70 
(m, lH, p-CH-Val); 1.82 (m, 2H, r-CH2-Arg); 2.03 (m, 2H, p-CH2-Arg); 3.23 (m, 2H, 6-CH2- 
Arg); 3.88 (d, lH, a-CH-Val); 4.56 (m, IH, a-CH-Arg); 7.84/7.86-8.20/8.22 (dd, 4H, arom 
PNA). 
2HCl. H- Val-Arg-pNA (6): 
As described for nHCl.H-D-Phe-Pip-X-pNA. 
Yield: 0.401 g (86%) Rt(BuOH/A~OHH~O 4: 1: 1 V/V/V): 0.40, [a]D = -5.7O c = 0.21 MeOH, ‘H 
NMR (CD30D): F = 1.05/1.07-l.OS/l.lO (dd, 6H, r-CHs/f-CHs-Val); 1.70-1.89 (m, 3H, r-CH2- 
Arg/p-CH-Val); 1.96i2.25 (dm, 2H, p-CHz-Arg); 3.26 (m, 2H, S-CH2-Arg); 3.82 (d, lH, a-CH- 
Val); 4.58 (m, IH, a-CH-Arg); 7.8517.87-8.2018.22 (dd, 4H, arom pNA). 
K-X-Arg-pNA.HCl 
The monomethyl ester of the malonic acid derivative was coupled with DCC/HOBt in DMP with 
2HCl.H-X-Arg-pNA in the presence of DIPEA for 1 hour at O°C and 16 hrs at room 
temperature. After filtration, the clear DMF phase was evaporated in vucuo. The residue was 
purified by counter current distribution with the solvent system: BuOWAcOH/H20 4: 1:5 v/v/v. 
Pure product was lyophilized from H20. 
R = DEMZ, X = Gly (34: 
Yield: 0.3988 (74%) Rt(BuOWAcOH/H20 4: 1: 1 v/v/v): 0.57 (K = 2.3 l), [a]D = -29.8O c = 0.27 
MeOH, ‘H NMR (D,O): 6 = 0.85 (t, 6H, CH3-diethylmalonic acid (2 x 3H)); 1.59 (m, 4H, p- 
CH&CH+Arg); 1.92 (q, 4H, -CH2- diethylmalonic acid (2 x 2H)); 3.19 (m, 2H, S-CH2-Arg); 
3.79 (s, 3H, OCHJ); 3.92 (s, 2H, CH2-Gly); 4.24 (m, lH, 
4H, arom pNA). 
a-CH-Arg); 7.2517.32-7.6417.73 (dd, 
Chromogenic substrates: The substrates were dissolved in distilled water to obtain 10 mM stock 
solutions. The concentration was determined at 3 16 nm using a molar extinction coefficient of 
12,500 Lmol-lcm-l. Stock solutions were stored in the dark at 4oC. 
Enzyme preparations: Pure human a-thrombin and human factor Xa samples were generous gifts 
of Dr. T. Lindhout (University of Limburg, Maastricht, The Netherlands). 
Kinetic parameters: The hydrolysis experiments were run in buffer A (0.05 M Tris-HCl, 0.1 M 
NaCl, pH = 7.35 containing 0.5 g/L bovine serum albumin (Sigma, Bornem, Belgium)) at 37OC. 
The liberation of p-nitroaniline was monitored at 405 nm in a dual wavelength (405-546 nm) 
spectrophotometer made in our workshop, using a personal computer for data recording. 
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TABLE ll 
Kinetics of Hydrolysis of a Number of Defined Substrates by Human a-Thrombin and 
Human Factor Xa in Buffer A at 37 oC. 
b-a-tbrombin 
Entry Substrate 
1 2HCl.H-D-Phe-Pip-Arg-pNA (l)# 6 
2 2HCl.H-DPhe-Pro-Arg-pNA (2) 3 
3 2HCl.H-DPhe-Pip-Lys-pNA (la) 65 
4 2HCl.H-D-Phe-Pro-Lys-pNA (2a) 35 
5 2HCl.H-D-Phe-Pip-Om-pNA (lb) 420 
6 HCLH-D-Phe-Pip-Nle-pNA (Id) 943 
I HCLH-D-Phe-Pro-Nle-pNA (2b) 88 
8 HCl.H-D-Phe-Pip-Glu-pNA (lc) 474 
9 2HCl.H-Gly-Arg-pNA (3) 2280 
10 ZHCl.H-Ala-Arg-pNA (4) 1140 
11 ZHCl.H-D-Ala-Arg-pNA (5) 4100 
12 ZHCLH-Val-Arg-pNA (6) 1240 
13 2HCl.H-D-Val-Arg-pNA (7) 4250 
14 MZ-Gly-Arg-pNA.HCI (3a) 2540 
15 MZ-Ala-Arg-pNA.HCl(4a) 1540 
16 MZ-D-Ala-Arg-pNA.HCI @a) 1330 
17 MZ-Aib-Arg-pNA.HCl* (SQ68) 830 
18 MZ-Val-Arg-pNA.HCl(6a) 1000 
19 MZ-D-Val-Arg-pNA.HCl(7a) 1310 
20 MMZ-Gly-Arg-pNA.HCl(3b) 1740 
21 MMZ-Ala-Arg-pNA.HCl(4b) 670 
22 DM.MZ-Gly-Arg-pNA.HCI (3~) 900 
23 DMMZ-Ala-Arg-pNA.HCl(4c) 570 
24 DEMZ-Gly-Arg-pNA.HCl(3d) 870 
25 Nas-Gly-Arg-pNA.HCl (3e) NH 
26 Tos-Gly-Arg-pNA.HCl(3f) NH 
bat 
s-1 
k&Kn 
(MS).’ 
237 3.95E7 
28 9.33E6 
118 1.82E6 
90 2.57E6 
5 1.19E4 
11 1.17E4 
7 7.9584 
0.4 8.44E2 
0.10 4.38El 
0.07 6.14El 
0.10 2.44El 
0.23 1.85E2 
0.3 7.06El 
12 4.7283 
108 7.0lE4 
0.06 4.5 1El 
0.46 5.54E2 
14 1.40E4 
0.15 1.15E2 
1 4.02E3 
17 2.54E4 
6 6.6X3 
4 7.02E3 
2 2.30E3 
174 8 4.60E4 
690 19 2.lSE2 
960 0.6 6.25E2 
NH 
NH 
NH 
NH 
4700 55 
5600 52 
3100 0.09 
3940 2.9 
2570 6 
1820 0.13 
6400 44 
7100 41 
2840 14 
2320 5 
120 2 
230 9 
1.17E4 
9.29E3 
2.90El 
7.38E2 
2.33E3 
7.14El 
6.88E3 
5.77E3 
4.93E3 
4,93E3** 
2.16E3 
1.67E4 
3.91E4 
h-factor Xa 
k cat 
s.1 
btKn 
(MSP 
NH: not hydrolyzed; *from reference 1; #substrate numbering as given in table I; **non Michaelis-Menten kinetics 
In a polystyrene microcuvette (total volume 500 &), buffer A and substrate solution were added 
to obtain a final substrate concentration between 1 to 2000 @I. After 5 min of incubation at 
37OC, enzyme solution was added to achieve a final concentration between 0.5 to 100 nM. The 
measurement was carried out in a thermostated cuvette-holder at 370C. The Michaelis constant 
( 
24 
and the catalytic constant (k,,J were obtained by measuring initial reaction velocities at 
di erent substrate concentrations (see table II). The data obtained were fitted using a non-linear 
regression procedure to the Michaelis-Menten equation. 
Continuous registration of the thrombin generation curve: The measurement is described in full 
detail in reference 1. Briefly, to 400 & defibrinated plasma in a polystyrene microcuvette was 
added 110 PL buffer A, 20 & phospholipid solution (phosphatidyl choline/phosphatidyl serine 
8:2, final concentration 1.5 PM) and 30 & substrate solution (final concentration 500 @I). After 
4 min of incubation at 37OC, 20 t.tL of a recombinant tissue factor solution (final concentration 6 
ng/mL) was added. Thrombm generation was started by adding 20 $ of a 0.5 M CaClz solution 
(final concentration 16.7 mM); during the measurement the temperature was kept at 37OC. The 
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FIG. 1 
Continuous optical density curves measured with different substrates in tissue factor 
triggered plasma. Upper frame: 0: 2HCl.H-Val-Arg-pNA (6) +: MZ-Aib-Arg-pNA.HCl 
(SQ68, reference); lower frame: 0: 2HClH-D-Phe-Pip-Orn-pNA (lb), n : DEMZ-Gly- 
Arg-pNA.HCl (3d). The optical density curve measured with HCl.H-D-Phe-Pip-Glu-pNA 
(lc) is omitted for clarity because it overlaps the curve measured with SQBS. The optical 
density curve is the time integral of a thrombin generation curve. The final slope of this 
curve is the result of the amidolytic activity of the cL2macroglobulin-thrombin complex. 
optical density was monitored at 405 nm, see Fig. 1. From the optical density curve, the first 
derivative can be calculated giving the enzyme concentration during the measurement. 
RESULTS AND CONCLUSION 
The thrombin generation curve is a rich source of information on the coagulation process in an 
individual plasma sample. With the usual subsampling techniques (22) the experimental effort to 
obtain such a curve prohibits its application to plasma samples of individual patients in the clinical 
laboratory. The continuous method published earlier (1) allows the registration of a thrombin 
generation curve in a single sample by optical monitoring of the thrombin-dependent splitting of a 
chromogenic substrate. This method lends itself to adaptation to laboratory automatons. It 
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requires thrombin substrates that are not exhausted by the thrombin generation in a plasma 
sample. Current substrates such as S2238 (Kabi) do not fulfill this requirement but another 
substrate, SQ68 (Serbio) did. In search for specific thrombin substrates that are specific but 
nevertheless are converted slowly, a series of 25 peptide p-nitroanilides with H-D-Phe-Pip-Arg- 
pNA and CH30-CO-CH2-CO-Aib-Arg-pNA as lead structures was synthesized. Classical 
solution methods were used and good yields were obtained. 
Substrates containing the H-D-Phe-Pip(Pro) sequence are hydrolyzed by thrombin even when 
neutral or acidic amino acid side chains are present at position PI. However, the efficient binding 
interaction of H-D-Phe-Pip(Pro) with thrombin results in K, values that were too low for our 
purpose. Varying P2/P3 residues appear to be the method of choice to arrive at substrates with 
higher Km values. In this study the amino acid at Pl was always an arginine residue, which 
ensures optimal interaction with the SI specificity pocket. The amino acid residue at P2 was 
systematically changed, incorporating: glycine, alanine and valine. This resulted in a gradual 
increasing occupancy of the hydrophobic binding pocket, leading to more important interaction 
and thus higher suitability for our purposes. The P3 modification was either omitted (a free N- 
terminus) or modified by a malonic acid derivative in which the methylene protons were changed 
for methyl- or ethyl groups. This resulted in fairly apolar aliphatic side chains which do not 
interact optimally with the aryl-binding site of thrombin. To achieve better interaction with the 
aryl-binding site, the N-terminus was modified by the introduction of an aromatic function. For 
this purpose the p-toluenesulfonyl- and p-naphthalenesulfonyl function were chosen (see table I). 
This however, did not result in compounds that could be hydrolyzed by thrombin. The similarity 
of compounds 3e and 3f to NAPAP suggests a similar binding mode in which the anilide bond 
points away from the Ser 195 side chain. 
In the continuous assay we need substrates which do not interact with factor Xa to minimize 
inhibition of thrombin formation and unwanted substrate hydrolysis by factor Xa. As can be seen 
from table II, compounds lb, lc, 3d and 6 appear to be suitable to be used as substrates in the 
continuous thrombin assay. A detailed biochemical evaluation of the applicability of these 
substrates in the continuous thrombin assay will be published elsewhere. 
Abbreviations 
Aib: aminoisobutyric acid (a-methylalanine); DCC: N,N’-dicyclohexylcarbodiimide; DCU: N,N’- 
dicyclohexylurea; DEMZ: diethylmalomc acid monomethyl ester; DIPEA: N,N- 
diisopropylethylamine; DMF: N,N-dimethylformamide; DMMZ: dimethylmalonic acid 
monomethyl ester; EtOAc: ethylacetate; MMZ: methylmalonic acid monomethyl ester; MZ: 
malonic acid monomethyl ester; pNA: para-nitroaniline; Nas: 2-naphthalenesulfonyl; Nle: 
norleucine; NMM: N-methylmorpholine; Orn: ornithine; Pip: pipecolic acid (homoproline); Tris: 
tris(hydroxymethyl)aminomethane; Tos: &toluenesulfonyl; UV: ultra-violet. 
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